Download PDF
Semin Thromb Hemost 2022; 48(08): 971-977
DOI: 10.1055/s-0041-1742083
Review Article

Interaction between Antiphospholipid Antibodies and Protein C Anticoagulant Pathway: A Narrative Review

Vittorio Pengo
1   Thrombosis Research Laboratory, University of Padova, Padova, Italy
2   Arianna Foundation on Anticoagulation, Bologna, Italy
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Thrombotic antiphospholipid syndrome (APS) is a condition in which thrombosis in venous, arterial, and/or small vessels is ascribed to the presence of antiphospholipid antibodies (aPL). Among the various proposed pathogenic theories to explain thrombotic APS, those involving the interaction between aPL and the protein C system have gained much consensus. Indeed, robust data show an acquired activated protein C resistance (APC-R) in these patients. The role of aPL in this impairment is clear, but the mechanism of action is uncertain, as the type of aPL and to what extent aPL are involved remains a gray area. Lupus anticoagulant (LA) is often associated with APC-R, but antibodies generating LA comprise those directed to β2-glycoprotein I and antiphosphatidylserine/prothrombin. Moreover, the induction of APC-R by aPL requires the presence of phospholipids and is suppressed by the presence of an excess of phospholipids. How phospholipids exposed on the cell membranes work in the system in vivo is unknown. Interestingly, acquired APC-R due to aPL might explain the clinical phenotypes of thrombotic APS. Indeed, the literature reports cases of both venous and arterial thromboembolism as well as skin necrosis, the latter observed in the severe form of protein C deficiency and in catastrophic APS.

Keywords

protein C - resistance - phospholipid - syndrome - antibodies - thrombosis - lupus anticoagulant


Publication History

Article published online:
12 January 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Esmon CT. The protein C pathway. Chest 2003; 124 (3, Suppl): 26S-32S
    CrossrefPubMedGoogle Scholar
  • 2 Padda IS, Patel P, Citla Sridhar D. Protein S and C. [Updated 2021 May 7]. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2021. . Available at: https://www.ncbi.nlm.nih.gov/books/NBK557814/
    Google Scholar
  • 3 Mosnier LO, Meijers JC, Bouma BN. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost 2001; 85 (01) 5-11
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Mosnier LO, Bouma BN. Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. Arterioscler Thromb Vasc Biol 2006; 26 (11) 2445-2453
    CrossrefPubMedGoogle Scholar
  • 5 Amiral J, Seghatchian J. Revisiting the activated protein C-protein S-thrombomodulin ternary pathway: impact of new understanding on its laboratory investigation. Transfus Apheresis Sci 2019; 58 (04) 538-544
    CrossrefPubMedGoogle Scholar
  • 6 ten Kate MK, van der Meer J. Protein S deficiency: a clinical perspective. Haemophilia 2008; 14 (06) 1222-1228
    CrossrefPubMedGoogle Scholar
  • 7 Esmon CT. Protein C anticoagulant system–anti-inflammatory effects. Semin Immunopathol 2012; 34 (01) 127-132
    CrossrefPubMedGoogle Scholar
  • 8 Cariou R, Tobelem G, Caen J. Circulating lupus-type anticoagulant, a risk factor for thrombosis by inhibition of protein C activation [in French]. C R Acad Sci III 1986; 303 (04) 113-118
    PubMedGoogle Scholar
  • 9 Cariou R, Tobelem G, Soria C, Caen J. Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant. N Engl J Med 1986; 314 (18) 1193-1194
    CrossrefPubMedGoogle Scholar
  • 10 Freyssinet JM, Wiesel ML, Gauchy J, Boneu B, Cazenave JP. An IgM lupus anticoagulant that neutralizes the enhancing effect of phospholipid on purified endothelial thrombomodulin activity–a mechanism for thrombosis. Thromb Haemost 1986; 55 (03) 309-313
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Cariou R, Tobelem G, Bellucci S. et al. Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells–inhibition of thrombomodulin-dependent protein C activation. Thromb Haemost 1988; 60 (01) 54-58
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Marciniak E, Romond EH. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 1989; 74 (07) 2426-2432
    CrossrefPubMedGoogle Scholar
  • 13 Malia RG, Kitchen S, Greaves M, Preston FE. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990; 76 (01) 101-107
    CrossrefPubMedGoogle Scholar
  • 14 Pötzsch B, Kawamura H, Preissner KT, Schmidt M, Seelig C, Müller-Berghaus G. Acquired protein C dysfunction but not decreased activity of thrombomodulin is a possible marker of thrombophilia in patients with lupus anticoagulant. J Lab Clin Med 1995; 125 (01) 56-65
    PubMedGoogle Scholar
  • 15 Lo SC, Salem HH, Howard MA, Oldmeadow MJ, Firkin BG. Studies of natural anticoagulant proteins and anticardiolipin antibodies in patients with the lupus anticoagulant. Br J Haematol 1990; 76 (03) 380-386
    CrossrefPubMedGoogle Scholar
  • 16 Borrell M, Sala N, de Castellarnau C, Lopez S, Gari M, Fontcuberta J. Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells. Thromb Haemost 1992; 68 (03) 268-272
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Bokarewa MI, Blombäck M, Egberg N, Rosén S. A new variant of interaction between phospholipid antibodies and the protein C system. Blood Coagul Fibrinolysis 1994; 5 (01) 37-41
    CrossrefPubMedGoogle Scholar
  • 18 Male C, Mitchell L, Julian J. et al. Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 2001; 97 (04) 844-849
    CrossrefPubMedGoogle Scholar
  • 19 Martinuzzo M, Forastiero R, Adamczuk Y, Cerrato G, Carreras LO. Activated protein C resistance in patients with anti-beta 2 glycoprotein I antibodies. Blood Coagul Fibrinolysis 1996; 7 (07) 702-704
    CrossrefPubMedGoogle Scholar
  • 20 Ruiz-Argüelles GJ, Garcés-Eisele J, Alarcón-Segovia D, Ruiz-Argüelles A. Activated protein C resistance phenotype and genotype in patients with primary antiphospholipid syndrome. Blood Coagul Fibrinolysis 1996; 7 (03) 344-348
    CrossrefPubMedGoogle Scholar
  • 21 Field SL, Chesterman CN, Hogg PJ. Dependence on prothrombin for inhibition of activated protein C activity by lupus antibodies. Thromb Haemost 2000; 84 (06) 1132-1133
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Regnault V, Béguin S, Wahl D, de Maistre E, Coenraad Hemker H, Lecompte T. Thrombinography shows acquired resistance to activated protein C in patients with lupus anticoagulants. Thromb Haemost 2003; 89 (02) 208-212
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Zuily S, Ait Aissa K, Membre A, Regnault V, Lecompte T, Wahl D. Thrombin generation in antiphospholipid syndrome. Lupus 2012; 21 (07) 758-760
    CrossrefPubMedGoogle Scholar
  • 24 Regnault V, Hemker HC, Wahl D, Lecompte T. Phenotyping the haemostatic system by thrombography–potential for the estimation of thrombotic risk. Thromb Res 2004; 114 (5–6) 539-545
    CrossrefPubMedGoogle Scholar
  • 25 Lecompte T, Wahl D, Perret-Guillaume C, Hemker HC, Lacolley P, Regnault V. Hypercoagulability resulting from opposite effects of lupus anticoagulants is associated strongly with thrombotic risk. Haematologica 2007; 92 (05) 714-715
    CrossrefPubMedGoogle Scholar
  • 26 Velasco-Rodríguez D, Laso RV, García-Raso A. et al. Thrombin generation in subjects with lupus anticoagulant without prior thrombosis or gestational morbidities. Thromb Res 2020; 196: 425-431
    CrossrefPubMedGoogle Scholar
  • 27 Arachchillage DR, Efthymiou M, Mackie IJ, Lawrie AS, Machin SJ, Cohen H. Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome. J Thromb Haemost 2014; 12 (11) 1801-1809
    CrossrefPubMedGoogle Scholar
  • 28 Efthymiou M, Arachchillage DRJ, Lane PJ. et al. Antibodies against TFPI and protein C are associated with a severe thrombotic phenotype in patients with and without antiphospholipid syndrome. Thromb Res 2018; 170: 60-68
    CrossrefPubMedGoogle Scholar
  • 29 Plasín-Rodríguez MA, Rodríguez-Pintó I, Patricio P. et al. The H1 haplotype of the endothelial protein C receptor protects against arterial thrombosis in patients with antiphospholipid syndrome. Thromb Res 2018; 169: 128-134
    CrossrefPubMedGoogle Scholar
  • 30 Devreese K, Peerlinck K, Arnout J, Hoylaerts MF. Laboratory detection of the antiphospholipid syndrome via calibrated automated thrombography. Thromb Haemost 2009; 101 (01) 185-196
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Khamashta MA, Asherson RA, Hughes GR. Possible mechanisms of action of the antiphospholipid binding antibodies. Clin Exp Rheumatol 1989; 7 (Suppl. 03) S85-S89
    PubMedGoogle Scholar
  • 32 Oosting JD, Derksen RH, Hackeng TM. et al. In vitro studies of antiphospholipid antibodies and its cofactor, beta 2-glycoprotein I, show negligible effects on endothelial cell mediated protein C activation. Thromb Haemost 1991; 66 (06) 666-671
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Oosting JD, Derksen RH, Bobbink IW, Hackeng TM, Bouma BN, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?. Blood 1993; 81 (10) 2618-2625
    CrossrefPubMedGoogle Scholar
  • 34 Oosting JD, Preissner KT, Derksen RH, de Groot PG. Autoantibodies directed against the epidermal growth factor-like domains of thrombomodulin inhibit protein C activation in vitro. Br J Haematol 1993; 85 (04) 761-768
    CrossrefPubMedGoogle Scholar
  • 35 Keeling DM, Wilson AJ, Mackie IJ, Isenberg DA, Machin SJ. Role of beta 2-glycoprotein I and anti-phospholipid antibodies in activation of protein C in vitro. J Clin Pathol 1993; 46 (10) 908-911
    CrossrefPubMedGoogle Scholar
  • 36 Tsakiris DA, Yasikoff ML, Wolf F, Marbet GA. Anticardiolipin antibodies do not seem to be associated with APC resistance in vivo or in vitro. Ann Hematol 1995; 71 (04) 195-198
    CrossrefPubMedGoogle Scholar
  • 37 Smirnov MD, Triplett DT, Comp PC, Esmon NL, Esmon CT. On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest 1995; 95 (01) 309-316
    CrossrefPubMedGoogle Scholar
  • 38 Esmon NL, Smirnov MD, Safa O, Esmon CT. Lupus anticoagulants, thrombosis and the protein C system. Haematologica 1999; 84 (05) 446-451
    PubMedGoogle Scholar
  • 39 Safa O, Hensley K, Smirnov MD, Esmon CT, Esmon NL. Lipid oxidation enhances the function of activated protein C. J Biol Chem 2001; 276 (03) 1829-1836
    CrossrefPubMedGoogle Scholar
  • 40 Matsuda J, Gohchi K, Kawasugi K, Gotoh M, Saitoh N, Tsukamoto M. Inhibitory activity of anti-beta 2-glycoprotein I antibody on factor Va degradation by activated-protein C and its cofactor protein S. Am J Hematol 1995; 49 (01) 89-91
    CrossrefPubMedGoogle Scholar
  • 41 Galli M, Ruggeri L, Barbui T. Differential effects of anti-beta2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C. Blood 1998; 91 (06) 1999-2004
    CrossrefPubMedGoogle Scholar
  • 42 Galli M, Willems GM, Rosing J. et al. Anti-prothrombin IgG from patients with anti-phospholipid antibodies inhibits the inactivation of factor Va by activated protein C. Br J Haematol 2005; 129 (02) 240-247
    CrossrefPubMedGoogle Scholar
  • 43 Atsumi T, Khamashta MA, Amengual O. et al. Binding of anticardiolipin antibodies to protein C via beta2-glycoprotein I (beta2-GPI): a possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system. Clin Exp Immunol 1998; 112 (02) 325-333
    CrossrefPubMedGoogle Scholar
  • 44 Carson CW, Comp PC, Rezaie AR, Esmon NL, Esmon CT. Antibodies to thrombomodulin are found in patients with lupus anticoagulant and unexplained thrombosis. J Rheumatol 2000; 27 (02) 384-390
    PubMedGoogle Scholar
  • 45 Izumi T, Pound ML, Su Z, Iverson GM, Ortel TL. Anti-beta(2)-glycoprotein I antibody-mediated inhibition of activated protein C requires binding of beta(2)-glycoprotein I to phospholipids. Thromb Haemost 2002; 88 (04) 620-626
    Article in Thieme ConnectPubMedGoogle Scholar
  • 46 Nojima J, Kuratsune H, Suehisa E. et al. Acquired activated protein C resistance is associated with the co-existence of anti-prothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus. Br J Haematol 2002; 118 (02) 577-583
    CrossrefPubMedGoogle Scholar
  • 47 Ieko M, Nakabayashi T, Takeda M, Naitoh S, Atsumi T, Koike T. The inhibition of protein C anticoagulant activity by anti-β2-glycoprotein I (β2GPI) antibodies isolated from patients with antiphospholipid syndrome by chromatography methods. Mod Rheumatol 2002; 12 (01) 44-49
    CrossrefPubMedGoogle Scholar
  • 48 Hwang KK, Yang CD, Yan W, Grossman JM, Hahn BH, Chen PP. A thrombin-cross-reactive anticardiolipin antibody binds to and inhibits the anticoagulant function of activated protein C. Arthritis Rheum 2003; 48 (06) 1622-1630
    CrossrefPubMedGoogle Scholar
  • 49 Safa O, Esmon CT, Esmon NL. Inhibition of APC anticoagulant activity on oxidized phospholipid by anti-beta2-glycoprotein I monoclonal antibodies. Blood 2005; 106 (05) 1629-1635
    CrossrefPubMedGoogle Scholar
  • 50 Nojima J, Kuratsune H, Suehisa E, Iwatani Y, Kanakura Y. Acquired activated protein C resistance associated with IgG antibodies against beta2-glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism. Clin Chem 2005; 51 (03) 545-552
    CrossrefPubMedGoogle Scholar
  • 51 Liestøl S, Sandset PM, Mowinckel MC, Wisløff F. Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants. J Thromb Haemost 2007; 5 (11) 2204-2210
    CrossrefPubMedGoogle Scholar
  • 52 van Hylckama Vlieg A, Montes R, Rosendaal FR, Hermida J. Autoantibodies against endothelial protein C receptor and the risk of a first deep vein thrombosis. J Thromb Haemost 2007; 5 (07) 1449-1454
    CrossrefPubMedGoogle Scholar
  • 53 de Laat B, Eckmann CM, van Schagen M, Meijer AB, Mertens K, van Mourik JA. Correlation between the potency of a beta2-glycoprotein I-dependent lupus anticoagulant and the level of resistance to activated protein C. Blood Coagul Fibrinolysis 2008; 19 (08) 757-764
    CrossrefPubMedGoogle Scholar
  • 54 Nojima J, Iwatani Y, Ichihara K. et al. Acquired activated protein C resistance is associated with IgG antibodies to protein S in patients with systemic lupus erythematosus. Thromb Res 2009; 124 (01) 127-131
    CrossrefPubMedGoogle Scholar
  • 55 Kaneshige R, Nojima J, Motoki Y, Tsuneoka H. aCL/β2GPI and aPS/PT show synergic thrombogenic effects in suppressing anticoagulant activity of APC and stimulating tissue factor expression and TNF-α secretion by mononuclear cells. Thromb Res 2019; 181: 52-58
    CrossrefPubMedGoogle Scholar
  • 56 Zuily S, de Laat B, Guillemin F. et al. Anti-domain I β2-glycoprotein I antibodies and activated protein C resistance predict thrombosis in antiphospholipid syndrome: TAC(I)T Study. J Appl Lab Med 2020; 5 (06) 1242-1252
    CrossrefPubMedGoogle Scholar
  • 57 Ramirez GA, Mackie I, Nallamilli S. et al. Anti-protein C antibodies and acquired protein C resistance in SLE: novel markers for thromboembolic events and disease activity?. Rheumatology (Oxford) 2021; 60 (03) 1376-1386
    CrossrefPubMedGoogle Scholar
  • 58 Pontara E, Cattini MG, Cheng C, Bison E, Denas G, Pengo V. Insight into the hypercoagulable state of high-risk thrombotic APS patients: contribution of aβ2GPI and aPS/PT antibodies. J Thromb Haemost 2021; 19 (03) 805-813
    CrossrefPubMedGoogle Scholar
  • 59 Cattini MG, Bison E, Pontara E, Cheng C, Denas G, Pengo V. Tetra positive thrombotic antiphospholipid syndrome: Major contribution of anti-phosphatidyl-serine/prothrombin antibodies to lupus anticoagulant activity. J Thromb Haemost 2020; 18 (05) 1124-1132
    CrossrefPubMedGoogle Scholar
  • 60 Cheng C, Pontara E, Tonello M. et al. Antibody profiles comprising anti phosphatidylserine/prothrombin differently affect thrombin generation and protein C resistance in antiphospholipid antibody carriers. Clin Chim Acta 2020; 510: 796-801
    CrossrefPubMedGoogle Scholar
  • 61 Ruiz-Arguelles GJ, Ruiz-Arguelles A, Deleze M, Alarcón-Segovia D. Acquired protein C deficiency in a patient with primary antiphospholipid syndrome. Relationship to reactivity of anticardiolipin antibody with thrombomodulin. J Rheumatol 1989; 16 (03) 381-383
    PubMedGoogle Scholar
  • 62 Halbmayer WM, Haushofer A, Schön R, Fischer M. Influence of lupus anticoagulant on a commercially available kit for APC-resistance. Thromb Haemost 1994; 72 (04) 645-646
    Article in Thieme ConnectPubMedGoogle Scholar
  • 63 Martorell JR, Muñoz-Castillo A, Gil JL. False positive activated protein C resistance test due to anti-phospholipid antibodies is corrected by platelet extract. Thromb Haemost 1995; 74 (02) 796-797
    Article in Thieme ConnectPubMedGoogle Scholar
  • 64 Amer L, Kisiel W, Searles RP, Williams Jr RC. Impairment of the protein C anticoagulant pathway in a patient with systemic lupus erythematosus, anticardiolipin antibodies and thrombosis. Thromb Res 1990; 57 (02) 247-258
    CrossrefPubMedGoogle Scholar
  • 65 Zivelin A, Gitel S, Griffin JH. et al. Extensive venous and arterial thrombosis associated with an inhibitor to activated protein C. Blood 1999; 94 (03) 895-901
    CrossrefPubMedGoogle Scholar
  • 66 Mahmoodi BK, Brouwer JL, Veeger NJ, van der Meer J. Hereditary deficiency of protein C or protein S confers increased risk of arterial thromboembolic events at a young age: results from a large family cohort study. Circulation 2008; 118 (16) 1659-1667
    CrossrefPubMedGoogle Scholar
  • 67 Francès C, Tribout B, Boisnic S. et al. Cutaneous necrosis associated with the lupus anticoagulant. Dermatologica 1989; 178 (04) 194-201
    CrossrefPubMedGoogle Scholar